The Complement System: An Important New Therapeutic Target in IgA Nephropathy

Area of Science:

• Nephrology
• Immunology

Background:

• IgA nephropathy (IgAN) is a leading cause of end-stage kidney disease globally.
• Historically, treatment for IgAN relied on supportive measures due to a lack of proven therapies.
• Recent advancements include promising new drugs in clinical trials.

Purpose of the Study:

• To review the emerging role of complement inhibitory drugs in IgA nephropathy treatment.
• To highlight the potential of iptacopan and other complement inhibitors.
• To discuss the utility of biomarkers in guiding IgAN therapy.

Main Methods:

• Review of clinical trial data for complement inhibitors in IgAN.
• Analysis of the mechanism of action for drugs targeting the complement cascade.
• Discussion of biomarker development for IgAN treatment selection and monitoring.

Main Results:

• Several complement inhibitors have demonstrated efficacy in reducing proteinuria in IgAN.
• Iptacopan, a selective alternative pathway inhibitor, showed rapid proteinuria reduction and received accelerated FDA approval.
• Complement activation generates detectable biomarkers in IgAN patients.

Conclusions:

• Complement inhibitory drugs are poised to become a cornerstone of IgAN treatment.
• Biomarkers are crucial for selecting optimal complement-targeted therapies and monitoring patient response.
• Personalized medicine approaches using biomarkers will advance IgAN patient care.